nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.12.2011

Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis

verfasst von: Jeffrey M. Peters, Jennifer E. Foreman, Frank J. Gonzalez

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3-4/2011

Einloggen, um Zugang zu erhalten

Abstract

Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) is a promising drug target since its agonists increase serum high-density lipoprotein; decrease low-density lipoprotein, triglycerides, and insulin associated with metabolic syndrome; improve insulin sensitivity; and decrease high fat diet-induced obesity. PPARβ/δ agonists also promote terminal differentiation and elicit anti-inflammatory activities in many cell types. However, it remains to be determined whether PPARβ/δ agonists can be developed as therapeutics because there are reports showing either pro- or anti-carcinogenic effects of PPARβ/δ in cancer models. This review examines studies reporting the role of PPARβ/δ in colon, breast, and lung cancers. The prevailing evidence would suggest that targeting PPARβ/δ is not only safe but could have anti-carcinogenic protective effects.

Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J., & Peters, J. M. (2006). The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicological Sciences, 90(2), 269–295.PubMed

Peters, J. M., Cheung, C., & Gonzalez, F. J. (2005). Peroxisome proliferator-activated receptor-α and liver cancer: Where do we stand? Journal of Molecular Medicine, 83(10), 774–785.PubMed

Klaunig, J. E., Babich, M. A., Baetcke, K. P., Cook, J. C., Corton, J. C., David, R. M., et al. (2003). PPARα agonist-induced rodent tumors: Modes of action and human relevance. Critical Reviews in Toxicology, 33(6), 655–780.PubMed

Thompson, E. A. (2007). PPARγ physiology and pathology in gastrointestinal epithelial cells. Molecules and Cells, 24(2), 167–176.PubMed

Choi, I. K., Kim, Y. H., Kim, J. S., & Seo, J. H. (2008). PPAR-γ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo. Investigational New Drugs, 26(3), 283–288.PubMed

Ptak-Belowska, A., Pawlik, M. W., Krzysiek-Maczka, G., Brzozowski, T., & Pawlik, W. W. (2007). Transcriptional upregulation of gastrin in response to peroxisome proliferator-activated receptor γ agonist triggers cell survival pathways. Journal of Physiology and Pharmacology, 58(4), 793–801.PubMed

Rohrl, C., Kaindl, U., Koneczny, I., Hudec, X., Baron, D. M., Konig, J. S., et al. (2011). Peroxisome-proliferator-activated receptors γ and β/δ mediate vascular endothelial growth factor production in colorectal tumor cells. Journal of Cancer Research and Clinical Oncology, 137(1), 29–39.PubMed

Girroir, E. E., Hollingshead, H. E., He, P., Zhu, B., Perdew, G. H., & Peters, J. M. (2008). Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice. Biochemical and Biophysical Research Communications, 371(3), 456–461.PubMed

Hall, J. M., & McDonnell, D. P. (2005). Coregulators in nuclear estrogen receptor action: From concept to therapeutic targeting. Molecular Interventions, 5(6), 343–357.PubMed

10.

Alvarez-Guardia, D., Palomer, X., Coll, T., Serrano, L., Rodriguez-Calvo, R., Davidson, M. M., et al. (2011). PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochimica et Biophysica Acta, 1811(2), 59–67.PubMed

11.

Barroso, E., Eyre, E., Palomer, X., & Vazquez-Carrera, M. (2011). The peroxisome proliferator-activated receptor β/δ (PPARβ/δ) agonist GW501516 prevents TNF-α-induced NF-κB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1. Biochemical Pharmacology, 81(4), 534–543.PubMed

12.

Coll, T., Alvarez-Guardia, D., Barroso, E., Gomez-Foix, A. M., Palomer, X., Laguna, J. C., et al. (2010). Activation of peroxisome proliferator-activated receptor-δ by GW501516 prevents fatty acid-induced nuclear factor-kB activation and insulin resistance in skeletal muscle cells. Endocrinology, 151(4), 1560–1569.PubMed

13.

Planavila, A., Rodriguez-Calvo, R., Jove, M., Michalik, L., Wahli, W., Laguna, J. C., et al. (2005). Peroxisome proliferator-activated receptor β/δ activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovascular Research, 65(4), 832–841.PubMed

14.

Rodriguez-Calvo, R., Serrano, L., Coll, T., Moullan, N., Sanchez, R. M., Merlos, M., et al. (2008). Activation of peroxisome proliferator-activated receptor β/δ (pparβ/δ) inhibits LPS-induced cytokine production in adipocytes by lowering NF-κB activity via ERK1/2. Diabetes, 57(8), 2149–2157.PubMed

15.

Shi, Y., Hon, M., & Evans, R. M. (2002). The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling. Proceedings of the National Academy of Science of the United States of America, 99(5), 2613–2618.

16.

Berger, J., Leibowitz, M. D., Doebber, T. W., Elbrecht, A., Zhang, B., Zhou, G., et al. (1999). Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects. Journal of Biological Chemistry, 274(10), 6718–6725.PubMed

17.

Leibowitz, M. D., Fievet, C., Hennuyer, N., Peinado-Onsurbe, J., Duez, H., Bergera, J., et al. (2000). Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Letters, 473(3), 333–336.PubMed

18.

Oliver, W. R., Jr., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., et al. (2001). A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proceedings of the National Academy of Science of the United States of America, 98(9), 5306–5311.

19.

Sprecher, D. L., Massien, C., Pearce, G., Billin, A. N., Perlstein, I., Willson, T. M., et al. (2007). Triglyceride: High-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist. Arteriosclerosis, Thrombrosis and Vascular Biology, 27(2), 359–365.

20.

Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., et al. (2003). Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proceedings of the National Academy of Science of the United States of America, 100(26), 15924–15929.

21.

Wang, Y. X., Lee, C. H., Tiep, S., Yu, R. T., Ham, J., Kang, H., et al. (2003). Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell, 113(2), 159–170.PubMed

22.

Wang, Y. X., Zhang, C. L., Yu, R. T., Cho, H. K., Nelson, M. C., Bayuga-Ocampo, C. R., et al. (2004). Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biology, 2(10), e294.PubMed

23.

Lee, C. H., Olson, P., Hevener, A., Mehl, I., Chong, L. W., Olefsky, J. M., et al. (2006). PPARδ regulates glucose metabolism and insulin sensitivity. Proceedings of the National Academy of Science of the United States of America, 103(9), 3444–3449.

24.

de la Monte, S. M., Tong, M., Lester-Coll, N., Jr Plater, M., & Wands, J. R. (2006). Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer's disease. Journal of Alzheimers Disease, 10(1), 89–109.

25.

de la Monte, S. M., & Wands, J. R. (2008). Alzheimer's disease is type 3 diabetes—Evidence reviewed. Journal of Diabetes Science and Technology, 2(6), 1101–1113.PubMed

26.

Kino, T., Rice, K. C., & Chrousos, G. P. (2007). The PPARδ agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition. European Journal of Clinical Invest, 37(5), 425–433.

27.

Lim, H. J., Park, J. H., Lee, S., Choi, H. E., Lee, K. S., & Park, H. Y. (2009). PPARδ ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR−/− mice. European Journal on Pharmacology, 622(1–3), 45–51.

28.

Liu, S., Hatano, B., Zhao, M., Yen, C. C., Kang, K., Reilly, S. M., et al. (2011). Role of peroxisome proliferator-activated receptor δ/β in hepatic metabolic regulation. Journal of Biological Chemistry, 286(2), 1237–1247.PubMed

29.

Nagasawa, T., Inada, Y., Nakano, S., Tamura, T., Takahashi, T., Maruyama, K., et al. (2006). Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. European Journal in Pharmacology, 536(1–2), 182–191.

30.

Shan, W., Nicol, C. J., Ito, S., Bility, M. T., Kennett, M. J., Ward, J. M., et al. (2008). Peroxisome proliferator-activated receptor-β/δ protects against chemically induced liver toxicity in mice. Hepatology, 47(1), 225–235.PubMed

31.

Shan, W., Palkar, P. S., Murray, I. A., McDevitt, E. I., Kennett, M. J., Kang, B. H., et al. (2008). Ligand activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicological Sciences, 105(2), 418–428.PubMed

32.

Gross, B., Hennuyer, N., Bouchaert, E., Rommens, C., Grillot, D., Mezdour, H., et al. (2011). Generation and characterization of a humanized PPARδ mouse model. British Journal of Pharmacology, 164(1), 192–208.

33.

Barish, G. D., Atkins, A. R., Downes, M., Olson, P., Chong, L. W., Nelson, M., et al. (2008). PPARδ regulates multiple proinflammatory pathways to suppress atherosclerosis. Proceedings of the National Academy of Science of the United States of America, 105(11), 4271–4276.

34.

Defaux, A., Zurich, M. G., Braissant, O., Honegger, P., & Monnet-Tschudi, F. (2009). Effects of the PPAR-β agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination. Journal of Neuroinflammation, 6(1), 15.PubMed

35.

Di Paola, R., Crisafulli, C., Mazzon, E., Esposito, E., Paterniti, I., Galuppo, M., et al. (2010). GW0742, a high-affinity PPAR-β/δ agonist, inhibits acute lung injury in mice. Shock, 33(4), 426–435.PubMed

36.

Di Paola, R., Esposito, E., Mazzon, E., Paterniti, I., Galuppo, M., & Cuzzocrea, S. (2010). GW0742, a selective PPAR-β/δ agonist, contributes to the resolution of inflammation after gut ischemia/reperfusion injury. Journal of Leukocyte Biology, 88(2), 291–301.PubMed

37.

Ding, G., Cheng, L., Qin, Q., Frontin, S., & Yang, Q. (2006). PPARδ modulates lipopolysaccharide-induced TNFα inflammation signaling in cultured cardiomyocytes. Journal of Molecular and Cellular Cardiology, 40(6), 821–828.PubMed

38.

Dunn, S. E., Bhat, R., Straus, D. S., Sobel, R. A., Axtell, R., Johnson, A., et al. (2010). Peroxisome proliferator-activated receptor δ limits the expansion of pathogenic Th cells during central nervous system autoimmunity. Journal of Experimental Medicine, 207(8), 1599–1608.PubMed

39.

Galuppo, M., Di Paola, R., Mazzon, E., Esposito, E., Paterniti, I., Kapoor, A., et al. (2011). GW0742, a high affinity PPAR-β/δ agonist reduces lung inflammation induced by bleomycin instillation in mice. International Journal of Immunopathology and Pharmacology, 23(4), 1033–1046.

40.

Galuppo, M., di Paola, R., Mazzon, E., Genovese, T., Crisafulli, C., Paterniti, I., et al. (2010). Role of PPAR-δ in the development of zymosan-induced multiple organ failure: An experiment mice study. Journal of Inflammation (London), 7(1), 12.

41.

Haskova, Z., Hoang, B., Luo, G., Morgan, L. A., Billin, A. N., Barone, F. C., et al. (2008). Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARβ/δ ligand GW0742. Inflammatory Research, 57(7), 314–321.

42.

Hollingshead, H. E., Morimura, K., Adachi, M., Kennett, M. J., Billin, A. N., Willson, T. M., et al. (2007). PPARβ/δ protects against experimental colitis through a ligand-independent mechanism. Digestive Diseases and Sciences, 52(11), 2912–2919.PubMed

43.

Kanakasabai, S., Chearwae, W., Walline, C. C., Iams, W., Adams, S. M., & Bright, J. J. (2010). Peroxisome proliferator-activated receptor δ agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology, 130(4), 572–588.PubMed

44.

Kanakasabai, S., Walline, C. C., Chakraborty, S., & Bright, J. J. (2011). PPARδ deficient mice develop elevated Th1/Th17 responses and prolonged experimental autoimmune encephalomyelitis. Brain Research, 1376, 101–112.PubMed

45.

Liang, Y. J., Chen, C. Y., Juang, S. J., Lai, L. P., Shyu, K. G., Wang, B. W., et al. (2010). Peroxisome proliferator-activated receptor δ agonists attenuated the C-reactive protein-induced pro-inflammation in cardiomyocytes and H9c2 cardiomyoblasts. European Journal in Pharmacology, 643(1), 84–92.

46.

Man, M. Q., Barish, G. D., Schmuth, M., Crumrine, D., Barak, Y., Chang, S., et al. (2007). Deficiency of PPARβ/δ in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. Journal of Investigative Dermatology, 128(2), 370–377.PubMed

47.

Minutoli, L., Antonuccio, P., Polito, F., Bitto, A., Squadrito, F., Irrera, N., et al. (2009). Peroxisome proliferator activated receptor β/δ activation prevents extracellular regulated kinase 1/2 phosphorylation and protects the testis from ischemia and reperfusion injury. Journal of Urology, 181, 1913–1921.PubMed

48.

Paterniti, I., Esposito, E., Mazzon, E., Galuppo, M., Di Paola, R., Bramanti, P., et al. (2010). Evidence for the role of peroxisome proliferator-activated receptor-β/δ in the development of spinal cord injury. Journal of Pharmacology and Experimental Therapeutics, 333(2), 465–477.PubMed

49.

Piqueras, L., Sanz, M. J., Perretti, M., Morcillo, E., Norling, L., Mitchell, J. A., et al. (2009). Activation of PPARβ/δ inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. Journal of Leukocyte Biology, 86(1), 115–122.PubMed

50.

Rival, Y., Beneteau, N., Taillandier, T., Pezet, M., Dupont-Passelaigue, E., Patoiseau, J. F., et al. (2002). PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. European Journal in Pharmacology, 435(2–3), 143–151.

51.

Rival, Y., Puech, L., Taillandier, T., Beneteau, N., Rouquette, A., Lestienne, F., et al. (2009). PPAR activators and COX inhibitors selectively block cytokine-induced COX-2 expression and activity in human aortic smooth muscle cells. European Journal in Pharmacology, 606(1–3), 121–129.

52.

Smeets, P. J., Teunissen, B. E., Planavila, A., de Vogel-van den Bosch, H., Willemsen, P. H., van der Vusse, G. J., et al. (2008). Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by PPARα and PPARδ. Journal of Biological Chemistry, 283(43), 29109–29118.PubMed

53.

Woo, C. H., Massett, M. P., Shishido, T., Itoh, S., Ding, B., McClain, C., et al. (2006). ERK5 activation inhibits inflammatory responses via peroxisome proliferator-activated receptor δ (PPARδ) stimulation. Journal of Biological Chemistry, 281(43), 32164–32174.PubMed

54.

Zingarelli, B., Piraino, G., Hake, P. W., O'Connor, M., Denenberg, A., Fan, H., et al. (2010). Peroxisome proliferator-activated receptor δ regulates inflammation via NF-kB signaling in polymicrobial sepsis. American Journal of Pathology, 177(4), 1834–1847.PubMed

55.

Almad, A., & McTigue, D. M. (2009). Chronic expression of PPAR-δ by oligodendrocyte lineage cells in the injured rat spinal cord. Journal of Comparative Neurology, 518(6), 785–799.

56.

Aung, C. S., Faddy, H. M., Lister, E. J., Monteith, G. R., & Roberts-Thomson, S. J. (2006). Isoform specific changes in PPARα and β in colon and breast cancer with differentiation. Biochemical and Biophysical Research Communications, 340(2), 656–660.PubMed

57.

Boiteux, G., Lascombe, I., Roche, E., Plissonnier, M. L., Clairotte, A., Bittard, H., et al. (2009). A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. International Journal of Cancer, 124(8), 1820–1828.

58.

Borland, M. G., Foreman, J. E., Girroir, E. E., Zolfaghari, R., Sharma, A. K., Amin, S. M., et al. (2008). Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits cell proliferation in human HaCaT keratinocytes. Molecular Pharmacology, 74(5), 1429–1442.PubMed

59.

Burdick, A. D., Bility, M. T., Girroir, E. E., Billin, A. N., Willson, T. M., Gonzalez, F. J., et al. (2007). Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits cell growth of human N/TERT-1 keratinocytes. Cellular Signaling, 19(6), 1163–1171.

60.

Di Loreto, S., D'Angelo, B., D'Amico, M. A., Benedetti, E., Cristiano, L., Cinque, B., et al. (2007). PPARβ agonists trigger neuronal differentiation in the human neuroblastoma cell line SH-SY5Y. Journal of Cellular Physiology, 211(3), 837–847.PubMed

61.

Hollingshead, H. E., Borland, M. G., Billin, A. N., Willson, T. M., Gonzalez, F. J., & Peters, J. M. (2008). Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis, 29(1), 169–176.PubMed

62.

Kim, D. J., Bility, M. T., Billin, A. N., Willson, T. M., Gonzalez, F. J., & Peters, J. M. (2006). PPARβ/δ selectively induces differentiation and inhibits cell proliferation. Cell Death and Differentiation, 13(1), 53–60.PubMed

63.

Marin, H. E., Peraza, M. A., Billin, A. N., Willson, T. M., Ward, J. M., Kennett, M. J., et al. (2006). Ligand activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) inhibits colon carcinogenesis. Cancer Research, 66(8), 4394–4401.PubMed

64.

Matsuura, H., Adachi, H., Smart, R. C., Xu, X., Arata, J., & Jetten, A. M. (1999). Correlation between expression of peroxisome proliferator-activated receptor β and squamous differentiation in epidermal and tracheobronchial epithelial cells. Molecular and Cellular Endocrinology, 147(1–2), 85–92.PubMed

65.

Nadra, K., Anghel, S. I., Joye, E., Tan, N. S., Basu-Modak, S., Trono, D., et al. (2006). Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor β/δ. Molecular and Cellular Biology, 26(8), 3266–3281.PubMed

66.

Sakuma, S., Endo, T., Kanda, T., Nakamura, H., Yamasaki, S., & Yamakawa, T. (2011). Synthesis of a novel human PPARδ selective agonist and its stimulatory effect on oligodendrocyte differentiation. Bioorganic and Medicinal Chemistry Letters, 21(1), 240–244.PubMed

67.

Saluja, I., Granneman, J. G., & Skoff, R. P. (2001). PPARδ agonists stimulate oligodendrocyte differentiation in tissue culture. Glia, 33(3), 191–204.PubMed

68.

Schmuth, M., Haqq, C. M., Cairns, W. J., Holder, J. C., Dorsam, S., Chang, S., et al. (2004). Peroxisome proliferator-activated receptor (PPAR)-β/δ stimulates differentiation and lipid accumulation in keratinocytes. Journal of Investigative Dermatology, 122(4), 971–983.PubMed

69.

Still, K., Grabowski, P., Mackie, I., Perry, M., & Bishop, N. (2008). The peroxisome proliferator activator receptor α/δ agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcified Tissue International, 83(4), 285–292.PubMed

70.

Tan, N. S., Michalik, L., Noy, N., Yasmin, R., Pacot, C., Heim, M., et al. (2001). Critical roles of PPARβ/δ in keratinocyte response to inflammation. Genes and Development, 15(24), 3263–3277.PubMed

71.

Varnat, F., Heggeler, B. B., Grisel, P., Boucard, N., Corthesy-Theulaz, I., Wahli, W., et al. (2006). PPARβ/δ regulates paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroenterology, 131(2), 538–553.PubMed

72.

Westergaard, M., Henningsen, J., Svendsen, M. L., Johansen, C., Jensen, U. B., Schroder, H. D., et al. (2001). Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. Journal of Investigative Dermatology, 116(5), 702–712.PubMed

73.

Yang, L., Olsson, B., Pfeifer, D., Jonsson, J. I., Zhou, Z. G., Jiang, X., et al. (2010). Knockdown of peroxisome proliferator-activated receptor-β induces less differentiation and enhances cell-fibronectin adhesion of colon cancer cells. Oncogene, 29(4), 516–526.PubMed

74.

He, T. C., Chan, T. A., Vogelstein, B., & Kinzler, K. W. (1999). PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell, 99(3), 335–345.PubMed

75.

Peters, J. M., & Gonzalez, F. J. (2009). Sorting out the functional role(s) of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in cell proliferation and cancer. Biochimica et Biophysica Acta, 1796(2), 230–241.PubMed

76.

Peters, J. M., Hollingshead, H. E., & Gonzalez, F. J. (2008). Role of peroxisome-proliferator-activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease. Clinical Science (London), 115(4), 107–127.

77.

Di-Poi, N., Tan, N. S., Michalik, L., Wahli, W., & Desvergne, B. (2002). Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway. Molecular Cell, 10, 721–733.PubMed

78.

Burdick, A. D., Kim, D. J., Peraza, M. A., Gonzalez, F. J., & Peters, J. M. (2006). The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation. Cellular Signaling, 18(1), 9–20.

79.

Braissant, O., Foufelle, F., Scotto, C., Dauca, M., & Wahli, W. (1996). Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology, 137(1), 354–366.PubMed

80.

Escher, P., Braissant, O., Basu-Modak, S., Michalik, L., Wahli, W., & Desvergne, B. (2001). Rat PPARs: Quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology, 142(10), 4195–4202.PubMed

81.

Berglund, L., Bjorling, E., Oksvold, P., Fagerberg, L., Asplund, A., Szigyarto, C. A., et al. (2008). A genecentric human protein atlas for expression profiles based on antibodies. Molecular and Cellular Proteomics, 7(10), 2019–2027.PubMed

82.

Uhlen, M., Bjorling, E., Agaton, C., Szigyarto, C. A., Amini, B., Andersen, E., et al. (2005). A human protein atlas for normal and cancer tissues based on antibody proteomics. Molecular and Cellular Proteomics, 4(12), 1920–1932.PubMed

83.

Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., et al. (2010). Towards a knowledge-based human protein atlas. Nature Biotechnology, 28(12), 1248–1250.PubMed

84.

Foreman, J. E., Chang, W.-C., Palkar, P. S., Zhu, B., Borland, M. G., Williams, J. L., et al. (2011). Functional characterization of peroxisome proliferator-activated receptor-β/δ expression in colon cancer. Molecular Carcinogenesis, 50(11), 884–900.

85.

Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883–899.PubMed

86.

Terzic, J., Grivennikov, S., Karin, E., & Karin, M. (2010). Inflammation and colon cancer. Gastroenterology, 138(6), 2101–2114. e2105.PubMed

87.

Gupta, R. A., Wang, D., Katkuri, S., Wang, H., Dey, S. K., & DuBois, R. N. (2004). Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nature Medicine, 10(3), 245–247.PubMed

88.

Wang, D., Wang, H., Guo, Y., Ning, W., Katkuri, S., Wahli, W., et al. (2006). Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression. Proceedings of the National Academy of Science of the United States of America, 103(50), 19069–19074.

89.

Zuo, X., Peng, Z., Moussalli, M. J., Morris, J. S., Broaddus, R. R., Fischer, S. M., et al. (2009). Targeted genetic disruption of peroxisome proliferator-activated receptor-δ and colonic tumorigenesis. Journal of the National Cancer Institute, 101(10), 762–767.PubMed

90.

Park, B. H., Vogelstein, B., & Kinzler, K. W. (2001). Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells. Proceedings of the National Academy of Science of the United States of America, 98(5), 2598–2603.

91.

Barak, Y., Liao, D., He, W., Ong, E. S., Nelson, M. C., Olefsky, J. M., et al. (2002). Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proceedings of the National Academy of Science of the United States of America, 99, 303–308.

92.

Harman, F. S., Nicol, C. J., Marin, H. E., Ward, J. M., Gonzalez, F. J., & Peters, J. M. (2004). Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis. Nature Medicine, 10(5), 481–483.PubMed

93.

Hollingshead, H. E., Killins, R. L., Borland, M. G., Girroir, E. E., Billin, A. N., Willson, T. M., et al. (2007). Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis, 28(12), 2641–2649.PubMed

94.

Stephen, R. L., Gustafsson, M. C., Jarvis, M., Tatoud, R., Marshall, B. R., Knight, D., et al. (2004). Activation of peroxisome proliferator-activated receptor δ stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Research, 64(9), 3162–3170.PubMed

95.

Yang, L., Zhou, Z. G., Zheng, X. L., Wang, L., Yu, Y. Y., Zhou, B., et al. (2008). RNA interference against peroxisome proliferator-activated receptor δ gene promotes proliferation of human colorectal cancer cells. Diseases of the Colon and Rectum, 51(3), 318–328.PubMed

96.

Takayama, O., Yamamoto, H., Damdinsuren, B., Sugita, Y., Ngan, C. Y., Xu, X., et al. (2006). Expression of PPARδ in multistage carcinogenesis of the colorectum: Implications of malignant cancer morphology. British Journal of Cancer, 95(7), 889–895.PubMed

97.

Yoshinaga, M., Taki, K., Somada, S., Sakiyama, Y., Kubo, N., Kaku, T., et al. (2010). The expression of both peroxisome proliferator-activated receptor δ and cyclooxygenase-2 in tissues is associated with poor prognosis in colorectal cancer patients. Digestive Diseases and Sciences, 56, 1194–1200.PubMed

98.

Ouyang, N., Williams, J. L., & Rigas, B. (2006). NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)δ expression in APC(min/+) mice proportionally to their tumor inhibitory effect: Implications for the role of PPARδ in carcinogenesis. Carcinogenesis, 27(2), 232–239.PubMed

99.

Yang, L., Zhang, H., Zhou, Z. G., Yan, H., Adell, G., & Sun, X. F. (2011). Biological function and prognostic significance of peroxisome proliferator-activated receptor δ in rectal cancer. Clinical Cancer Research, 17(11), 3760–3770.

100.

Gimble, J. M., et al. (1998). Expression of peroxisome proliferator activated receptor mRNA in normal and tumorigenic rodent mammary glands. Biochemical and Biophysical Research Communications., 253(3), 813–817.PubMed

101.

Foreman, J. E., Sharma, A. K., Amin, S., Gonzalez, F. J., & Peters, J. M. (2010). Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits cell growth in a mouse mammary gland cancer cell line. Cancer Letters, 288, 219–225.PubMed

102.

Guilbaud, N. F., Gas, N., Dupont, M. A., & Valette, A. (1990). Effects of differentiation-inducing agents on maturation of human MCF-7 breast cancer cells. Journal of Cellular Physiology, 145(1), 162–172.PubMed

103.

Girroir, E. E., Hollingshead, H. E., Billin, A. N., Willson, T. M., Robertson, G. P., Sharma, A. K., et al. (2008). Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology, 243(1–2), 236–243.PubMed

104.

Palkar, P. S., Borland, M. G., Naruhn, S., Ferry, C. H., Lee, C., Sk, U. H., et al. (2010). Cellular and pharmacological selectivity of the PPARβ/δ antagonist GSK3787. Molecular Pharmacology, 78(3), 419–430.PubMed

105.

Conway, J. G., Tomaszewski, K. E., Olson, M. J., Cattley, R. C., Marsman, D. S., & Popp, J. A. (1989). Relationship of oxidative damage to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and Wy-14,643. Carcinogenesis, 10(3), 513–519.PubMed

106.

Ghosh, M., Ai, Y., Narko, K., Wang, Z., Peters, J. M., & Hla, T. (2009). PPARδ is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer. Prostaglandins and Other Lipid Mediators, 88(3–4), 97–100.PubMed

107.

Yin, Y., Russell, R. G., Dettin, L. E., Bai, R., Wei, Z. L., Kozikowski, A. P., et al. (2005). Peroxisome proliferator-activated receptor δ and γ agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Research, 65(9), 3950–3957.PubMed

108.

Pollock, C. B., Yin, Y., Yuan, H., Zeng, X., King, S., Li, X., et al. (2011). PPARδ activation acts cooperatively with 3-phosphoinositide-dependent protein kinase-1 to enhance mammary tumorigenesis. PLoS One, 6(1), e16215.PubMed

109.

Shearer, B. G., & Hoekstra, W. J. (2003). Recent advances in peroxisome proliferator-activated receptor science. Current Medicinal Chemistry, 10(4), 267–280.PubMed

110.

Narkar, V. A., Downes, M., Yu, R. T., Embler, E., Wang, Y. X., Banayo, E., et al. (2008). AMPK and PPARδ agonists are exercise mimetics. Cell, 134(3), 405–415.PubMed

111.

Tachibana, K., Kobayashi, Y., Tanaka, T., Tagami, M., Sugiyama, A., Katayama, T., et al. (2005). Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms. Nuclear Receptor, 3, 3.PubMed

112.

Szeles, L., Poliska, S., Nagy, G., Szatmari, I., Szanto, A., Pap, A., et al. (2010) Research resource: Transcriptome profiling of genes regulated by RXR and its permissive and nonpermissive partners in differentiating monocyte-derived dendritic cells. Molecular Endocrinology, 24(11),2218-2231.

113.

Schug, T. T., Berry, D. C., Shaw, N. S., Travis, S. N., & Noy, N. (2007). Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell, 129(4), 723–733.PubMed

114.

Schug, T. T., Berry, D. C., Toshkov, I. A., Cheng, L., Nikitin, A. Y., & Noy, N. (2008). Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARβ/δ to RAR. Proceedings of the National Academy of Science of the United States of America, 105(21), 7546–7551.

115.

Kannan-Thulasiraman, P., Seachrist, D. D., Mahabeleshwar, G. H., Jain, M. K., & Noy, N. (2010). Fatty acid-binding protein 5 and PPARβ/δ are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. Journal of Biological Chemistry, 285(25), 19106–19115.PubMed

116.

Bissahoyo, A., Pearsall, R. S., Hanlon, K., Amann, V., Hicks, D., Godfrey, V. L., et al. (2005). Azoxymethane is a genetic background-dependent colorectal tumor initiator and promoter in mice: Effects of dose, route, and diet. Toxicological Sciences, 88(2), 340–345.PubMed

117.

Dietrich, W. F., Lander, E. S., Smith, J. S., Moser, A. R., Gould, K. A., Luongo, C., et al. (1993). Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell, 75(4), 631–639.PubMed

118.

Moser, A. R., Dove, W. F., Roth, K. A., & Gordon, J. I. (1992). The Min (multiple intestinal neoplasia) mutation: Its effect on gut epithelial cell differentiation and interaction with a modifier system. Journal of Cell Biology, 116(6), 1517–1526.PubMed

119.

Rieck, M., Meissner, W., Ries, S., Muller-Brusselbach, S., & Muller, R. (2008). Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR) β/δ: A comparative analysis of PPAR-selective agonists and all-trans retinoic acid. Molecular Pharmacology, 74(5), 1269–1277.PubMed

120.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.PubMed

121.

Pedchenko, T. V., Gonzalez, A. L., Wang, D., DuBois, R. N., & Massion, P. P. (2008). Peroxisome proliferator-activated receptor β/δ expression and activation in lung cancer. American Journal of Respiratory Cell and Molecular Biology, 39(6), 689–696.PubMed

122.

Foreman, J. E., Sorg, J. M., McGinnis, K. S., Rigas, B., Williams, J. L., Clapper, M. L., et al. (2009). Regulation of peroxisome proliferator-activated receptor-β/δ by the APC/β-CATENIN pathway and nonsteroidal antiinflammatory drugs. Molecular Carcinogenesis, 48(10), 942–952.PubMed

123.

Fukumoto, K., Yano, Y., Virgona, N., Hagiwara, H., Sato, H., Senba, H., et al. (2005). Peroxisome proliferator-activated receptor δ as a molecular target to regulate lung cancer cell growth. FEBS Letters, 579(17), 3829–3836.PubMed

124.

Ali, F. Y., Egan, K., Fitzgerald, G. A., Desvergne, B., Wahli, W., Bishop-Bailey, D., et al. (2005). Role of prostacyclin receptor versus PPARβ with treprostinil sodium on lung fibroblast proliferation. American Journal of Respiratory Cell and Molecular Biology, 34(2), 242–246.PubMed

125.

Han, S., Ritzenthaler, J. D., Wingerd, B., & Roman, J. (2005). Activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) increases the expression of prostaglandin E2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein β. Journal of Biological Chemistry, 280(39), 33240–33249. [RETRACTED (2011). Journal of Biological Chemistry, 286 (28) 25416].

126.

Han, S., Ritzenthaler, J. D., Zheng, Y., & Roman, J. (2008). PPARβ/δ agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: The involvement of PI3K and NF-κB signals. American Journal Physiology-Lung Cellular and Molecular Physiology, 294(6), L1238–L1249.

127.

Han, S., Ritzenthaler, J. D., Sun, X., Zheng, Y., & Roman, J. (2009). Activation of peroxisome proliferator-activated receptor β/δ induces lung cancer growth via peroxisome proliferator-activated receptor coactivator γ-1alpha. American Journal of Respiratory Cell and Molecular Biology, 40(3), 325–331.PubMed

128.

Sun, X., Ritzenthaler, J. D., Zhong, X., Zheng, Y., Roman, J., & Han, S. (2009). Nicotine stimulates PPARβ/δ expression in human lung carcinoma cells through activation of PI3K/mTOR and suppression of AP-2α. Cancer Research, 69(16), 6445–6453.PubMed

129.

He, P., Borland, M. G., Zhu, B., Sharma, A. K., Amin, S., El-Bayoumy, K., et al. (2008). Effect of ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in human lung cancer cell lines. Toxicology, 254, 112–117.PubMed

130.

Forman, B. M., Chen, J., & Evans, R. M. (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proceedings of the National Academy of Science of the United States of America, 94(9), 4312–4317.

131.

Keith, R. L., Miller, Y. E., Hoshikawa, Y., Moore, M. D., Gesell, T. L., Gao, B., et al. (2002). Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Research, 62(3), 734–740.PubMed

132.

Keith, R. L., Miller, Y. E., Hudish, T. M., Girod, C. E., Sotto-Santiago, S., Franklin, W. A., et al. (2004). Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Research, 64(16), 5897–5904.PubMed

133.

Nemenoff, R., Meyer, A. M., Hudish, T. M., Mozer, A. B., Snee, A., Narumiya, S., et al. (2008). Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor γ. Cancer Prevention Research (Philadelphia), 1(5), 349–356.

134.

Fauti, T., Müller-Brüsselbach, S., Kreutzer, M., Rieck, M., Meissner, W., Rapp, U., et al. (2005). Induction of PPARβ and prostacyclin (PGI₂) synthesis by Raf signaling: Failure of PGI₂ to activate PPARβ. FEBS Journal, 273(1), 170–179.

135.

Muller-Brusselbach, S., Ebrahimsade, S., Jakel, J., Eckhardt, J., Rapp, U. R., Peters, J. M., et al. (2007). Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARβ/δ gene. International Journal of Oncology, 31(3), 607–611.PubMed

136.

Engels, E. A., Wu, X., Gu, J., Dong, Q., Liu, J., & Spitz, M. R. (2007). Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Research, 67(13), 6520–6527.PubMed

137.

Kilgore, K. S., & Billin, A. N. (2008). PPARβ/δ ligands as modulators of the inflammatory response. Current Opinion in Investigational Drugs, 9(5), 463–469.PubMed

138.

Tauler, J., & Mulshine, J. L. (2009). Lung cancer and inflammation: Interaction of chemokines and hnRNPs. Current Opinion in Pharmacology, 9(4), 384–388.PubMed

139.

Kramer, D. K., Al-Khalili, L., Guigas, B., Leng, Y., Garcia-Roves, P. M., & Krook, A. (2007). Role of AMP kinase and PPARδ in the regulation of lipid and glucose metabolism in human skeletal muscle. Journal of Biological Chemistry, 282(27), 19313–19320.PubMed

140.

Kramer, D. K., Al-Khalili, L., Perrini, S., Skogsberg, J., Wretenberg, P., Kannisto, K., et al. (2005). Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor δ. Diabetes, 54(4), 1157–1163.PubMed

141.

Kefas, B. A., Cai, Y., Ling, Z., Heimberg, H., Hue, L., Pipeleers, D., et al. (2003). AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. Journal of Molecular Endocrinology, 30(2), 151–161.PubMed

142.

Meisse, D., Van de Casteele, M., Beauloye, C., Hainault, I., Kefas, B. A., Rider, M. H., et al. (2002). Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. FEBS Letters, 526(1–3), 38–42.PubMed

143.

Rattan, R., Giri, S., Singh, A. K., & Singh, I. (2005). 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. Journal of Biological Chemistry, 280(47), 39582–39593.PubMed

144.

Xiang, X., Saha, A. K., Wen, R., Ruderman, N. B., & Luo, Z. (2004). AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochemical and Biophysical Research Communications, 321(1), 161–167.PubMed

145.

Li, J., Jiang, P., Robinson, M., Lawrence, T. S., & Sun, Y. (2003). AMPK-β1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression. Carcinogenesis, 24(5), 827–834.PubMed

146.

Bility, M. T., Devlin-Durante, M. K., Blazanin, N., Glick, A. B., Ward, J. M., Kang, B. H., et al. (2008). Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits chemically-induced skin tumorigenesis. Carcinogenesis, 29(12), 2406–2414.PubMed

147.

Bility, M. T., Zhu, B., Kang, B. H., Gonzalez, F. J., & Peters, J. M. (2010). Ligand activation of peroxisome proliferator-activated receptor-β/δ and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis. Toxicological Sciences, 113(1), 27–36.PubMed

148.

Kim, D. J., Akiyama, T. E., Harman, F. S., Burns, A. M., Shan, W., Ward, J. M., et al. (2004). Peroxisome proliferator-activated receptor β (δ)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. Journal of Biological Chemistry, 279(22), 23719–23727.PubMed

149.

Kim, D. J., Murray, I. A., Burns, A. M., Gonzalez, F. J., Perdew, G. H., & Peters, J. M. (2005). Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits epidermal cell proliferation by down-regulation of kinase activity. Journal of Biological Chemistry, 280(10), 9519–9527.PubMed

150.

Kim, D. J., Prabhu, K. S., Gonzalez, F. J., & Peters, J. M. (2006). Inhibition of chemically-induced skin carcinogenicity by sulindac is independent of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ). Carcinogenesis, 27(5), 1105–1112.PubMed

151.

Peters, J. M., Lee, S. S. T., Li, W., Ward, J. M., Gavrilova, O., Everett, C., et al. (2000). Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β/δ. Molecular and Cellular Biology, 20, 5119–5128.PubMed

152.

Zhu, B., Bai, R., Kennett, M. J., Kang, B. H., Gonzalez, F. J., & Peters, J. M. (2011). Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-β/δ and inhibition of cyclooxygenase 2. Molecular Cancer Therapeutics, 9(12), 3267–3277.

153.

Pais, R., Silaghi, H., Silaghi, A. C., Rusu, M. L., & Dumitrascu, D. L. (2009). Metabolic syndrome and risk of subsequent colorectal cancer. World Journal of Gastroenterology, 15(41), 5141–5148.PubMed

154.

Prizment, A. E., Flood, A., Anderson, K. E., & Folsom, A. R. (2010). Survival of women with colon cancer in relation to precancer anthropometric characteristics: The Iowa Women's Health Study. Cancer Epidemiology, Biomarkers and Prevention, 19(9), 2229–2237.PubMed

155.

Tsugane, S., & Inoue, M. (2010). Insulin resistance and cancer: Epidemiological evidence. Cancer Science, 101(5), 1073–1079.PubMed

156.

Wolin, K. Y., Carson, K., & Colditz, G. A. (2011). Obesity and cancer. Oncologist, 15(6), 556–565.

157.

Vosper, H., Khoudoli, G. A., & Palmer, C. N. (2003). The peroxisome proliferator activated receptor delta is required for the differentiation of THP-1 monocytic cells by phorbol ester. Nuclear Receptor, 1(1), 9.PubMed

158.

Werling, U., Siehler, S., Litfin, M., Nau, H., & Gottlicher, M. (2001). Induction of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor delta by valproic acid and its teratogenic derivatives. Molecular Pharmacology, 59(5), 1269–1276.PubMed

159.

Liou, J. Y., Ghelani, D., Yeh, S., & Wu, K. K. (2007). Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3ε. Cancer Research, 67(7), 3185–3191.PubMed

160.

Wu, K. K., & Liou, J. Y. (2009). Cyclooxygenase inhibitors induce colon cancer cell apoptosis via PPARδ– > 14–3–3ε pathway. Methods in Molecular Biology, 512, 295–307.PubMed

Titel: Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis
verfasst von: Jeffrey M. Peters
Jennifer E. Foreman
Frank J. Gonzalez
Publikationsdatum: 01.12.2011
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3-4/2011
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-011-9320-1

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

ASS schützt nicht vor Brustkrebsrezidiven

02.05.2024 Mammakarzinom Nachrichten

Nützt nichts und ist vielleicht sogar schädlich: In einer Phase-3-Studie konnten täglich 300 mg ASS keine Brustkrebsrezidive bei Frauen vermeiden, die ein hohes Risiko für eine Tumorrückkehr aufwiesen. Tendenziell traten unter ASS sogar häufiger Rezidive auf als unter Placebo.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis

Abstract

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

ASS schützt nicht vor Brustkrebsrezidiven

Update Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3-4/2011

Cannabinoids, endocannabinoids, and cancer

15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in?

Basic aspects of tumor cell fatty acid-regulated signaling and transcription factors

EET signaling in cancer

Prostaglandin catabolic enzymes as tumor suppressors

MicroRNA and AU-rich element regulation of prostaglandin synthesis

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

ASS schützt nicht vor Brustkrebsrezidiven

Update Onkologie